Lead Product(s): Mometasone Furoate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: LYR-210
Highest Development Status: Phase II Product Type: Small molecule
Deal Size: $147.0 million Upfront Cash: $12.0 million
Deal Type: Partnership June 02, 2021
LYR-210 is an anti-inflammatory, intra-nasal drug matrix in late-stage development that is designed to treat chronic rhinosinusitis (CRS), a debilitating inflammatory disease of the nasal passages.